5TTS

Jak3 with covalent inhibitor 4


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.34 Å
  • R-Value Free: 0.263 
  • R-Value Work: 0.202 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.

Thorarensen, A.Dowty, M.E.Banker, M.E.Juba, B.Jussif, J.Lin, T.Vincent, F.Czerwinski, R.M.Casimiro-Garcia, A.Unwalla, R.Trujillo, J.I.Liang, S.Balbo, P.Che, Y.Gilbert, A.M.Brown, M.F.Hayward, M.Montgomery, J.Leung, L.Yang, X.Soucy, S.Hegen, M.Coe, J.Langille, J.Vajdos, F.Chrencik, J.Telliez, J.B.

(2017) J. Med. Chem. 60: 1971-1993

  • DOI: 10.1021/acs.jmedchem.6b01694
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant effort during the past 2 decades, identification of hig ...

    Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant effort during the past 2 decades, identification of highly selective JAK3 inhibitors has eluded the scientific community. A significant effort within our research organization has resulted in the identification of the first orally active JAK3 specific inhibitor, which achieves JAK isoform specificity through covalent interaction with a unique JAK3 residue Cys-909. The relatively rapid resynthesis rate of the JAK3 enzyme presented a unique challenge in the design of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwanted off-target reactivity. This effort resulted in the identification of 11 (PF-06651600), a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor 11 led to its evaluation in several human clinical studies.


    Organizational Affiliation

    Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide R&D , 1 Burtt Road, Andover, Massachusetts 01810, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tyrosine-protein kinase JAK3
A
321Homo sapiensMutation(s): 1 
Gene Names: JAK3
EC: 2.7.10.2
Find proteins for P52333 (Homo sapiens)
Go to Gene View: JAK3
Go to UniProtKB:  P52333
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
7KU
Query on 7KU

Download SDF File 
Download CCD File 
A
1-{(3R)-3-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}propan-1-one
C14 H19 N5 O
HTWQEUNJZRNASZ-SNVBAGLBSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.34 Å
  • R-Value Free: 0.263 
  • R-Value Work: 0.202 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 47.369α = 90.00
b = 75.754β = 90.00
c = 89.550γ = 90.00
Software Package:
Software NamePurpose
BUSTERrefinement
PDB_EXTRACTdata extraction
SCALEPACKdata scaling
DENZOdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2016-11-04 
  • Released Date: 2017-02-22 
  • Deposition Author(s): Vajdos, F.F.

Revision History 

  • Version 1.0: 2017-02-22
    Type: Initial release
  • Version 1.1: 2017-03-22
    Type: Database references